Investigating drug-resistant tuberculosis and HIV co-infection
Multidrug-resistant tuberculosis and HIV: Composition of Strains and biomarkers of treatment response
This study is looking at how multidrug-resistant tuberculosis (MDR-TB) affects people who also have HIV, and it wants to find out how well they respond to treatment by checking their blood and sputum over the first 16 weeks of therapy, all while focusing on patients in KwaZulu-Natal, South Africa.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10924443 on NIH RePORTER |
What this research studies
This research focuses on understanding how multidrug-resistant tuberculosis (MDR-TB) interacts with HIV in patients. It aims to identify biomarkers that indicate how well patients respond to treatment and to explore the genetic diversity of tuberculosis strains in those co-infected with HIV. Participants will be enrolled at the beginning of their MDR-TB therapy and will undergo regular blood and sputum tests for the first 16 weeks to track their treatment progress. The study is conducted in KwaZulu-Natal, South Africa, a region with high rates of both MDR-TB and HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multidrug-resistant tuberculosis who are also co-infected with HIV.
Not a fit: Patients who do not have multidrug-resistant tuberculosis or HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients suffering from both MDR-TB and HIV.
How similar studies have performed: Previous research has shown promising results in understanding the interactions between drug-resistant tuberculosis and HIV, but this specific approach is innovative and aims to fill existing knowledge gaps.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Cudahy, Patrick George Tobias — Yale University
- Study coordinator: Cudahy, Patrick George Tobias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.